• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of gastroenterology and hepatology >Cost-utility and cost-benefit analyses: how did we get here and where are we going?
【24h】

Cost-utility and cost-benefit analyses: how did we get here and where are we going?

机译：成本效用和成本效益分析：我们如何到达这里以及我们要去哪里？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cost-utility and cost-benefit analyses are currently the only tools available for evaluating whether the cost of an intervention is a good use of resources when compared with other ways that money could be spent on health care (allocative efficiency). Cost-utility analyses assess health in terms of length and quality of life using the quality adjusted life year whilst cost-benefit analyses measure health in monetary terms. The measurement of health gain with either approach has a number of problems and the accuracy of these measures is uncertain. Cost-benefit analysis has certain advantages when measuring improvements in mild diseases such as irritable bowel disease and dyspepsia, which are common problems in gastroenterology. The results of cost-benefit analysis may provide more transparent guidance for policy makers, doctors and patients.
机译：与可以将其他金钱用于卫生保健的方式（分配效率）相比，成本效用和成本效益分析是目前唯一可用于评估干预成本是否是对资源的良好利用的工具。成本效用分析使用质量调整后的生命年，根据寿命和生活质量评估健康状况，而成本效益分析则以货币形式衡量健康状况。用这两种方法来衡量健康状况都有许多问题，并且这些方法的准确性还不确定。在测量轻度疾病（如肠易激病和消化不良）的改善时，成本效益分析具有某些优势，而这些疾病是胃肠病学中的常见问题。成本效益分析的结果可能为决策者，医生和患者提供更透明的指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号